Key Takeaways
- Volume-led growth, margin reset: Revenue grew on strong volumes in HPPC and textiles, but EBITDA margin settled into a 13%-13.5% "new normal" as the surfactant-heavy mix and institutional seeding costs re-base profitability.
- Institutional business is the long bet: Buzil-Rossari contributed ~₹60 crore this quarter and is on track for ₹250 crore this year, but management will keep investing for two more years before operating leverage kicks in.
- Exports are the growth engine: Exports are growing faster than domestic, with new distributor initiatives in Bangladesh, Vietnam and Egypt starting to convert; management targets a 25%-30% export share over the next two years.
- Capacity build-out timed to Reliance: A 30,000 MT ethoxylation expansion at Dahej will commission through the year, but management sees FY26-27 as the year of full utilization, coinciding with Reliance's ethylene oxide supply coming online.
- What to watch next quarter: Whether the institutional business stays on the ₹250 crore trajectory, any release from working capital by September, and how the new Bangladesh and Egypt distributor initiatives convert into orders.
The Margin Reset: Why 13%-13.5% Is the New Normal
- Mix shift toward surfactants: The acquisitions of Unitop and Tristar brought large surfactant businesses whose raw material purchasing patterns and customer credit terms structurally compress margins relative to Rossari's legacy specialty chemicals profile.
- Other expenses stepped up: Higher freight costs (container rates 2-3x normal, though stabilizing), travel, exhibition spending, maintenance (a ₹3-4 crore one-off from a Tristar plant shutdown), and consulting fees for an HR restructuring all hit the quarter.
- Institutional seeding is a deliberate drag: Buzil-Rossari requires heavy field investment in people, service and dispensing equipment. Management explicitly accepts this margin headwind to build scale.
- Employee costs are structural, not one-off: The increase reflects new hires over the past year plus annual increments, not a spike that will reverse.
- No path back to pre-COVID margins: When asked about returning to 15%-17% EBITDA margins, management called 13%-13.5% the new normal and declined to set that as a target.
Sunil Chari: "Ankur ji, now, the major business is surfactants at Unitop which was of course planned at Rossari as Ethoxylation earlier, and I think we should consider this as a new normal in terms of EBITDA margins."
Institutional Business: The Long-Gestation Bet
- Scale today, profit later: The institutional cleaning and hygiene business (Buzil-Rossari) is running at a ~₹250 crore annualized topline. Management wants it to at least double in two years, and only at ₹500-600 crore does it expect operating leverage to visibly lift margins.
- The model is service-intensive: The business supplies concentrated chemicals with dispensers to airports, malls, food service and hospitals, requiring a large field force and equipment investment. It competes as a full basket provider, not just a chemical supplier.
- Product pipeline building: New launches based on povidone-iodine (the active in Betadine) and other products are planned, with hospital hygiene flagged as a large future opportunity, though timelines remain vague.
- Management is patient: The company is willing to seed this business for several more years before it contributes meaningfully to group margins.
Ketan Sablok: "I have a feeling that this number needs to at least double in the next 2 years and maybe two years down the line we will start seeing some operating leverage flowing in."
Export-Led Volume Growth
- Exports outpacing domestic: Export revenue is growing faster than domestic across HPPC, with textile exports also firming up slowly. The company is targeting 25%-30% export share over the next two years, up from the current ~₹120 crore per quarter against ~₹20-25 crore of imports.
- Bangladesh traction building: A new distributor is in place and forex issues have eased considerably. Management calls the Bangladesh market larger than India's and expects progressively better traction, weighted to H2.
- Vietnam and Egypt are the new fronts: Initiatives begun last quarter in Vietnam are playing out now; Egypt initiatives started this quarter. Both are early-stage distributor-led pushes.
- Freight headwind stabilizing: Container rates are 2-3x normal but appear to be plateauing. Container and ship availability improved slightly versus the January-March quarter. All contracts are FOB with transparent CIF pass-through, so the company does not speculate on freight.
- Domestic market gets a relative benefit: Higher freight makes competing imports more expensive, and India's growing domestic availability of raw materials (acrylic acid, butyl acrylic from BPCL; acetic acid from GNFC) improves the competitive position of local manufacturers.
Sunil Chari: "we do not want to earn from the freight."
HPPC: Cross-Selling and Product Substitution
- Unitop's mix is transforming: At acquisition, agrochemical products were 60%-65% of Unitop's sales. That ratio is now roughly 50-50 agro to non-agro, and this quarter agro would have been closer to 45% due to seasonality.
- In-house substitution is underway: Esters, SMOs, SML, SMS and MRO products that Unitop previously outsourced are now manufactured at Rossari's Dahej plant. Cocoaminopropyl betaines and CDEA production has also started in-house.
- New product launches flowing: A range of esters for personal care, polysorbates, biosurfactants, silicone block polymers, and green chemistry products (bio-scouring agent, green hydro) have moved from R&D into commercial production.
- Cosmetics/Purple business scaling: The personal care sub-segment grew substantially QoQ, with polysorbates and esters gaining traction in both export and domestic markets, though management declined to disclose its size.
- Agrochemical season improving: This season is better than last year, with a good monsoon driving formulator confidence. Collections remain stable, not worsened.
Textiles: Price-Led Volume Recovery
- Falling finished-goods prices are driving volumes: Lower prices have translated into materially higher offtake, particularly from home textile exporters serving the US market. Order books with Indian and Bangladeshi customers are full.
- A reclassification distorts the base: A product was moved from the Textiles segment to HPPC in Q2 of last year, making the Q1 FY24 textile base appear lower than it truly was.
- Export initiatives beginning to convert: The Bangladesh and Vietnam distributor pushes from last quarter are now contributing to textile export revenue, with Egypt added this quarter. Management expects good traction in H2.
Capacity Build-Out and the Reliance Link
- Dahej ethoxylation expansion: 30,000 MT of ethoxylation capacity is being added at Unitop's Dahej facility, with phased commissioning through the current year. The broader Dahej expansion is expected to complete by March 2025.
- Utilization depends on Reliance: Most of the expansion is ethylene oxide-based. Management is waiting for Reliance's ethylene oxide capacity expansion to come online simultaneously, and sees FY26-27 as the right year for 100% utilization.
- Dubai subsidiary as a global vehicle: A Dubai entity has been incorporated to serve as the holding structure for any future international expansion, whether marketing offices or small manufacturing facilities. Specific geographies are still in planning.
Ketan Sablok: "Any new set up which we may plan to do in any other country, we would like to do it through this Dubai subsidiary."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin range | 13%-13.5% for the full year | FY25 |
| Institutional business topline | ₹250 crore | FY25 |
| Institutional business margin inflection | Operating leverage to start flowing in once topline reaches ₹500-600 crore | ~2 years out |
| Dahej expansion completion | All expansion work finished | By March 2025 |
| Ethoxylation capacity utilization | 100% utilization of new capacities | FY26-27 |
| Export revenue share | 25%-30% of total revenue | Next 2 years |
| Working capital release | Some release of funds from working capital | By September 2024 |
| Textile export traction | Good traction from Bangladesh/Vietnam initiatives | H2 FY25 (balance part of year) |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue from operations | ₹489.7 crore, +19.3% YoY from ₹410.6 crore |
| EBITDA | ₹64.9 crore, +12.5% YoY from ₹57.7 crore |
| EBITDA margin | 13.3%, compared to 14.1% in Q1 FY24; drop due to higher freight, travel, maintenance and selling costs |
| PAT | ₹34.9 crore, +19.5% YoY from ₹29.2 crore |
| HPPC division revenue | ₹365 crore, +21% YoY from ₹301 crore |
| Textile Specialty Chemicals revenue | ₹98 crore, +21% YoY from ₹81 crore |
| Animal Health and Nutrition revenue | ₹27 crore, compared to ₹29 crore in Q1 FY24 |
| Revenue mix | HPPC 75%, TSC 20%, AHN 5% |
| Exports share of revenue | 24%-25%, up from 20% in Q1 FY24; YoY growth close to 50% |
| Institutional cleaning business revenue | ₹60 crore for the quarter; full-year FY25 target of ₹250 crore |
| Ethoxylation capacity utilization | 90%+ at both Tristar and Unitop; overall average utilization 55%-60% |
| Cash CAPEX outflow guidance for FY25 | ~₹100 crore, covering Unitop and Rossari expansions plus small AHN vitamin premix and minerals facility |
| Freight expense increase | 35%-40% YoY increase over Q1 FY24 |
| One-off other expenses | ₹3-4 crore, including Tristar plant shutdown maintenance (12-15 days) and HR restructuring consulting |